Monoclonal antibodies

Related products

• 

  Crohn's disease

  5-aminosalicylic acid

  【Product name】CANASA

  [English common name]5-Aminosalicylic acid

  [Chinese common name]5-aminosalicylic acid

  [English name]5-ASA; 5-Amino salicylic acidl, Mesalazine

  [Chinese other name]5-amino-2-hydroxybenzoic acid, mesalazine

  [Indications] For the treatment of ulcerative colitis, Crohn's disease; suppositories for the treatment of ulcerative proctitis, can also be combined with mesalazine tablets.

  [Usage and Dosage] Oral: Adult, ulcerative colitis (acute attack): 4 times a day, 1g each time; maintenance treatment, 3 times a day, 0.5g each time.
  Crohn's disease: 4 times a day, 1g each time. For children over 2 years old, take 20-30mg per kilogram of body weight per day, in divided doses.
  Suppository: Adult, 1-2 times a day, 1 suppository each time. Children over the age of two, follow the doctor's advice.

  [Storage] The tablets should be stored at room temperature (15-25 °C) and should not be taken after the expiration date. Suppositories should be stored at room temperature (15-25 °C) in the original package and should not be used after the expiration date.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Crohn's disease

  BCG

  【Product name】IMMUCYST, Immunobladder, TICE BCG

  [English common name]Bacillus Calmette-Guerin vaccine

  [Chinese common name]BCG

  [English name]

  [Chinese other name]

  [Indications] This product (BCG immunotherapeutic agent) is suitable for intravesical use and treatment of primary recurrent carcinoma in situ (CIS) of the bladder to reduce the frequency of tumor recurrence. It is indicated for the treatment of carcinoma in situ with or without papillary tumors. However, it is not suitable for the treatment of papilloma that occurs alone. This product is also used as a remedy for the bladder to respond to other in situ carcinoma (CIS) treatments. Treatment and prevention of primary or recurrent carcinoma in situ or superficial papilloma after transurethral resection (TA and T1).

  [Usage and Dosage] Intravesical treatment and prevention of bladder carcinoma in situ (CIS) should be started 7 to 14 days after biopsy or transurethral resection. In a single dose of 3 vials, this product (BCG immunotherapeutic agent) was administered by intravesical injection once a week for 6 weeks (induction therapy). Each dose (3 bottles of prepared vials) was diluted with 50 ml of bacteria and diluted with preservative-free saline to a total of 53 ml. The urethral catheter is inserted into the bladder under aseptic conditions, guiding the contents of the bladder, and then slowly injecting 50 ml of the suspension of the product by gravity, and then taking out the catheter. During the first hour after perfusion, the patient should be placed in the prone, lying down and lying on the left and right sides for 15 minutes. The patient can then stand but maintain the suspension for 60 minutes for a total of 2 hours. It should be taught to urinate if needed for less time. . At the end of the 2 hours, all patients urinate in a sitting position for safety reasons. Patients should be taught to maintain adequate water. The true number of perfusions required to achieve the optimal response is still unknown. Most responding patients are achieved with 6 to 12 perfusions.

  [Storage] The medicine should be placed in a refrigerator of 2 to 8 degrees Celsius (not frozen); if it deteriorates or expires, it can no longer be used.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Crohn's disease , Behcet disease

  Azathioprine

  【Product name】Yimulan, IMURAN

  [English common name]Azathioprine

  [Chinese common name]Azathioprine

  [English name]Azathioprine

  [Chinese other name]Milan

  [indications]
  1.Acute and chronic leukemia,CorrectChronic myeloid leukemiaThe short-term effect is better, the effect is fast, but the remission period is short;
  2. Acquired hemolytic anemia, idiopathic thrombocytopenic purpura, systemic lupus erythematosus;
  3. ChronicRheumatoid arthritis, chronic active hepatitis (hepatitis associated with autoimmunity), primary biliary cirrhosis;
  4. Hyperthyroidism,Myasthenia gravis;
  5. Others: chronic non-specific ulcerative colitis, segmental enteritis, multiple radiculitis, lupus nephritis, proliferative nephritis, Wegener's granulomatosis, etc.

  【Dosage】
  1. Oral daily 1.5mg ~ 4mg / kg, once a day or divided into oral.
  2. Allogeneic transplantation, daily 2mg ~ 5mg / kg, once a day or divided into oral.
  3. Leukemia, daily 1mg ~ 3mg / kg, once a day or divided into oral.

  [Storage] shading, sealed and stored.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Crohn's disease , Behcet disease

  Infliximab

  【Product name】REMICADE, Remicade

  [English common name]Infliximab

  [Chinese common name]Infliximab

  [English name]

  [Chinese other name]

  [indications]
  Rheumatoid Arthritis
  This product is a disease-control anti-rheumatic drug. For patients with moderate to severe active rheumatoid arthritis, this product can be used in combination with methotrexate:
  · Reduce symptoms and signs;
  · Improve physical function and prevent disability in patients.
  Crohn's disease
  For patients with moderate to severe active Crohn's disease who are not well received by traditional treatment, this product can be used for:
  · Reduce symptoms and signs;
  · Achieve and maintain clinical efficacy;
  · Promote mucosal healing;
  · Improve the quality of life;
  · Reduce the amount of corticosteroids or stop using corticosteroids.
  Tracheal Crohn's disease
  For patients with fistile Crohn's disease, this product can be used for:
  Reduce the number of intestinal-cutaneous fistulas and rectal-vaginal fistulas to promote and maintain fistula healing;
  · Reduce symptoms and signs;
  · Improve the quality of life.
  Ankylosing spondylitis
  For patients with active ankylosing spondylitis, this product can be used for:
  · Alleviate symptoms and signs, including increasing the range of activity;
  · Improve physical function;
  · Improve the quality of life.
  psoriasis
  For patients with psoriasis, this product can be used for:
  Adult patients with chronic severe plaque psoriasis who require systemic treatment and are ineffective, contraindicated or tolerant to other systems such as cyclosporine, methotrexate or photochemotherapy. This product is intended for use only in patients who are treated under close supervision by a physician and regularly followed up by a physician.

  【Dosage】
  Usage: intravenous infusion.
  Rheumatoid Arthritis
  The product was administered 3 mg/kg for the first time, and then the same dose was administered once every 8 weeks after the second week and the sixth week after the first administration and thereafter. This product should be combined with methotrexate. For patients with poor efficacy, consider adjusting the dose to 10 mg/kg and/or adjusting the medication interval to 4 weeks.
  Moderate and severe active Crohn's disease, fistula Crohn's disease
  The product was administered 5 mg/kg for the first time, and then the same dose was administered once every 8 weeks after the second week and the sixth week after the first administration and thereafter. For patients with poor efficacy, consider adjusting the dose to 10 mg/kg.
  Ankylosing spondylitis
  The product was administered 5 mg/kg for the first time, and then the same dose was administered once every 6 weeks after the second week and the sixth week after the first administration and thereafter.
  User guides
  Sterility should be performed.
  1. Calculate the dosage and determine the number of bottles used in this product: This product contains 100mg of infliximab per bottle, and calculate the total amount of the solution to be prepared.
  2. Dissolve each bottle of medicine with 10 ml of sterile water for injection using a syringe equipped with a 21 gauge (0.8 mm) or smaller needle: remove the flip of the vial, wipe the top of the vial with a medical alcohol swab, and insert the syringe needle into the vial Cover, inject sterile water for injection. If the vacuum in the vial has been destroyed, the bottle cannot be used. Gently rotate the vial to dissolve the powder. Avoid shaking for a long time or with force. Do not oscillate. Foam may appear during the dissolution of the drug. After 5 minutes of storage, the solution should be colorless or light yellow, and the milk is white. Since infliximab is a protein, there may be some translucent particles in the solution. If opaque particles, discoloration or other substances appear in the solution, they cannot be used any more.
  3. Dilute the sterile aqueous solution of this product to 250 ml with 0.9% sodium chloride injection: withdraw the same amount of liquid from the 250 ml 0.9% sodium chloride injection bottle or bag as the sterile injectable aqueous solution of this product. The sterile aqueous solution for injection of this product is completely injected into the infusion bottle or bag and gently mixed.
  4. The infusion time should not be less than 2 hours: the infusion set should be equipped with a built-in, sterile, pyrogen-free, low protein binding filter (pore size ≤ 1.2 μm). Unused infusions should not be stored for further use.
  5. The physical and biochemical compatibility studies of this product in combination with other drugs have not been carried out, and this product should not be infused simultaneously with other drugs.
  Products administered parenterally should be visually inspected for the presence of particulate matter or discoloration prior to administration. If opaque particles, discoloration, or other foreign matter are found, the drug may not be used.
  Plaque psoriasis
  The product was administered 5 mg/kg for the first time, and then the same dose was administered once every 8 weeks after the second week and the sixth week after the first administration and thereafter. If the patient does not respond after week 14 (ie, after 4 doses), the product should not be treated.
  Psoriasis patients re-administered
  Patients with psoriasis have limited experience with a single administration after 20 weeks, suggesting a reduction in the effectiveness of the product compared to the initial induction therapy and an increase in mild to moderate infusion response.
  After relapse of the disease, limited experience with repeated induction therapy showed an increase in infusion response (including severe reactions) compared to 8-week maintenance therapy.
  If treatment interruption is maintained, it is not recommended to initiate induction therapy again and should be re-administered according to maintenance therapy.

  [Storage]Store at 2-8 °C in the dark.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.